Research Projects & Grants

For Profit Organization

• Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy ofMR-146 in Participants with Stage 2 Neurotrophic Keratopathy: An Open-Label Part 1 and a Double-Masked Part 2, Role: Investigator, Oyster Point, Inc. (A Viatris Company), (05/2026 - 05/2027) Status: Approved

Internal

• The incidence of dry eye syndrome in patients with pituitary tumors with and without transsphenoidal hypophysectomy, Role: Investigator, LLU Dept. of Ophthalmology, (07/2019) Status: Approved